A PHASE 3 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN PREVIOUSLY UNTREATED OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (VIALE-C): A 6-MONTH UPDATE

EHA Library, Andrew H. Wei, 294956

A RANDOMISED EVALUATION OF LOW-DOSE ARA-C PLUS AC220 (QUIZARTINIB) VERSUS LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE LI-1 TRIAL

EHA Library, Mike Dennis, 294957

ALL-TRANS RETINOIC ACID IMPROVES SURVIVAL IN ELDERLY AML PATIENTS BY DELAYING DECITABINE RESISTANCE DEVELOPMENT: RESULTS OF A RANDOMIZED TRIAL (DECIDER STUDY)

EHA Library, Michael Lübbert, 294958

ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)

EHA Library, Courtney DiNardo, 294959

POSTTRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM A RETROSPECTIVE CHART REVIEW STUDY

EHA Library, James D. Griffin, 294960

10-DAY DECITABINE AND VENETOCLAX (DEC10-VEN) VS. INTENSIVE CHEMOTHERAPY (IC) IN ACUTE MYELOID LEUKEMIA (AML): A PROPENSITY SCORE MATCHED ANALYSIS STRATIFIED BY RISK OF TREATMENT-RELATED MORTALITY

EHA Library, Abhishek Maiti, 294961

COMPARATIVE RESULTS OF AZACITIDINE AND DECITABINE FROM A LARGE PROSPECTIVE PHASE 3 STUDY IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Amer M. Zeidan, 294962

PHASE IB/II STUDY OF THE IDH1-MUTANT INHIBITOR IVOSIDENIB WITH THE BCL2 INHIBITOR VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED HEMATOLOGIC MALIGNANCIES

EHA Library, Courtney DiNardo, 294963

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS

EHA Library, Naval Daver, 294964

TEMPORAL TRENDS IN OVERALL SURVIVAL AMONG ADULT NON-APL AML PATIENTS IN THE PERIOD 2000-2016: A DANISH POPULATION-BASED STUDY

EHA Library, Lasse Hjort Jakobsen, 294965

PROGNOSTIC SIGNIFICANCE OF CONCOMITANT GENE MUTATIONS IN INTENSIVELY TREATED PATIENTS WITH IDH1/2 MUTATED AML

EHA Library, Matthieu Duchmann, 294966

EMERGING MUTATIONS AT RELAPSE IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WHO RECEIVED GILTERITINIB THERAPY IN THE PHASE 3 ADMIRAL TRIAL

EHA Library, Catherine C. Smith, 294967

MOLECULAR LANDSCAPE AND PROGNOSTIC IMPACT OF FLT3 INTERNAL TANDEM DUPLICATION INSERTION SITE IN ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE RATIFY STUDY (ALLIANCE 10603)

EHA Library, Frank Rücker, 294968

FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR (CCAR) T CELL THERAPY IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Fang Liu, 294969

MULTI-OMICS DATA INTEGRATION IDENTIFIES IGHV-INDEPENDENT BIOMARKER ASSOCIATED WITH MTOR-MYC-OXPHOS FOR AGGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Junyan Lu, 294970

DETERMINANTS OF THE PROTEOME LANDSCAPE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Fabienne Meier-Abt, 294971

MIR-29 INFLUENCES CD40 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Sonali Sharma, 294972

ACTIVE AKT SIGNALING TRIGGERS CLL TOWARDS RICHTER'S TRANSFORMATION VIA OVER-ACTIVATION OF NOTCH1

EHA Library, Stuart Blakemore, 294973

MECHANISMS OF ADAPTATION TO IBRUTINIB IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Gabriela Forestieri, 294974

FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL

EHA Library, Othman Al-Sawaf, 294975

EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I)

EHA Library, Arnon P. Kater, 294976

CLL2-GIVE, A PROSPECTIVE, OPEN-LABEL, MULTICENTER PHASE-II TRIAL OF OBINUTUZUMAB (GA101, G), IBRUTINIB (I), PLUS VENETOCLAX (VE) IN UNTREATED PATIENTS WITH CLL WITH 17P DELETION / TP53 MUTATION

EHA Library, Henriette Huber, 294977

FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT

EHA Library, Tanya Siddiqi, 294978

ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ASCEND FINAL RESULTS

EHA Library, Paolo Ghia, 294979

A TIME-LIMITED TREATMENT WITH IBRUTINIB ALONG WITH A REDUCED NUMBER OF IMMUNOCHEMOTHERAPY COURSES LEADS TO PROFOUND AND LONG-LASTING RESPONSES IN PREVIOUSLY UNTREATED CLL PATIENTS

EHA Library, Anne-Sophie Michallet, 294980

BTK AND PLCG2 MUTATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RELAPSING ON IBRUTINIB: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) STUDY BASED ON REAL-WORLD EVIDENCE

EHA Library, Lydia Scarfò, 294981

INITIAL RESULTS OF A MULTICENTER, INVESTIGATOR-INITIATED STUDY OF MRD DRIVEN TIME LIMITED THERAPY WITH ZANUBRUTINIB, OBINUTUZUMAB AND VENETOCLAX

EHA Library, Jacob D. Soumerai, 294982

ACALABRUTINIB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA: MATURE RESULTS FROM PHASE 2 STUDY DEMONSTRATING DURABLE REMISSIONS AND LONG-TERM TOLERABILITY

EHA Library, John C. Byrd, 294983

KINETICS OF RESPONSE IN THE PERIPHERAL BLOOD PREDICTS LONG TERM RESPONSES TO IBRUTINIB + VENETOCLAX TREATMENT FOR RELAPSED/REFRACTORY CLL IN THE BLOODWISE TAP CLARITY TRIAL.

EHA Library, Andrew Rawstron, 294984

IDENTIFICATION OF A DRUG-ABLE DOPAMINE RECEPTOR MEDIATED PATHWAY THAT IS CRITICAL FOR CML STEM CELL SURVIVAL

EHA Library, Jake Ritchie, 294985

MODEL-BASED INFERENCE AND CLASSIFICATION OF IMMUNOLOGICAL CONTROL MECHANISMS FROM TKI CESSATION AND DOSE REDUCTION IN CML PATIENTS

EHA Library, Ingmar Glauche, 294986

MECHANISTIC AND THERAPEUTIC INSIGHTS INTO PRC2 REPROGRAMMING IN BLAST PHASE CML

EHA Library, Rebecca Mitchell, 294987

MECHANISTIC INSIGHTS INTO THE INHIBITION OF T REGULATORY CELLS BY DASATINIB IN CML PATIENTS WITH CLONAL LYMPHOCYTOSIS

EHA Library, Patrick Harrington, 294988

PERIPHERAL BLOOD CD26+ LEUKEMIA STEM CELLS AND TKI DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF PROSPECTIVE FLOWER-TFR STUDY

EHA Library, Anna Sicuranza, 294989

ASCIMINIB IN HEAVILY PRETREATED PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) SENSITIVE TO TYROSINE KINASE INHIBITOR (TKI) THERAPY

EHA Library, Tim Hughes, 294990

MAJOR MOLECULAR RESPONSE IS THE THRESHOLD FOR NGS ANALYSIS AND RESISTANT BCR-ABL1 MUTATION DETECTION IN CML

EHA Library, Katerina Machova Polakova, 294991

INTERIM ANALYSIS FROM THE OPTIC TRIAL, A DOSE-RANGING STUDY OF 3 STARTING DOSES OF PONATINIB

EHA Library, Jorge Cortes, 294992

DASATINIB PLUS PEG-INTERFERON ALPHA 2B COMBINATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: 48-MONTHS RESULTS OF A PHASE 2 STUDY ON BEHALF OF THE FRENCH GROUP OF CML (FI-LMC)

EHA Library, Lydia ROY, 294993

HIGH LEVEL OF SUCCESSFUL TKI DISCONTINUATION OUTSIDE CLINICAL TRIALS - A POPULATION-BASED STUDY FROM THE SWEDISH CML REGISTRY

EHA Library, Hjalmar Flygt, 294994

INTEGRATED LANDSCAPE OF GENE MUTATIONS AND COPY NUMBER ALTERATIONS IN CLONAL HEMATOPOIESIS: ANALYSIS IN 10,852 JAPANESE INDIVIDUALS

EHA Library, Ryunosuke Saiki, 294995

HUMAN IPSC-BASED MODEL OF GATA2 DEFICIENCY REVEALS IMPAIRED ENDOTHELIAL-HEMATOPOIETIC DEVELOPMENT

EHA Library, Alessandra Giorgetti, 294996

TRANSCRIPTIONAL REGULATION OF HEMATOPOIETIC STEM CELLS IN AGING AND MYELODYSPLASTIC SYNDROME REVEALS DDIT3 AS A POTENTIAL DRIVER OF TRANSFORMATION

EHA Library, Teresa Ezponda, 294997

COMBINED COHESIN-RUNX1 DEFICIENCY SYNERGISTICALLY PERTURBS CHROMATIN LOOPING AND CAUSES MYELODYSPLASTIC SYNDROMES

EHA Library, Yotaro Ochi, 294998

DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY HIGH THROUGHPUT SINGLE CELL RNA SEQUENCING INTEGRATED WITH HIGHLY SENSITIVE GENOTYPING METHOD.

EHA Library, Masahiro Nakagawa, 294999

A PHASE III PLACEBO-CONTROLLED TRIAL OF CC-486 IN PATIENTS WITH RED BLOOD CELL TRANSFUSION-DEPENDENT (RBC-TD) ANEMIA AND THROMBOCYTOPENIA DUE TO IPSS LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

EHA Library, Guillermo Garcia-Manero, 295000

APR-246 COMBINED WITH AZACITIDINE IN TP53 MUTATED MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA. A PHASE 2 STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM)

EHA Library, Thomas Cluzeau, 295001

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA

EHA Library, Lionel ADES, 295002

TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESA)

EHA Library, Uwe Platzbecker, 295003

RANDOMIZED OPEN-LABELED ACADEMIC TRIAL COMPARING ‘G-CSF PRIOR AZA' WITH STANDARD AZA THERAPY IN HIGH RISK MDS PATIENTS.

EHA Library, Tomas Stopka, 295004

ANTI-TIM-3 ANTIBODY MBG453 IN COMBINATION WITH HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): A PHASE 1 STUDY

EHA Library, Uma Borate, 295005

GENETIC AND CLINICAL RISK PREDICTION IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Nico Gagelmann, 295006

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN MDS PATIENTS: PHASE 1B RESULTS

EHA Library, Sallman David, 295007

A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME

EHA Library, Amer M. Zeidan, 295008

DEFECTIVE GRANULOPOIESIS IN CONGENITAL NEUTROPENIA IS CAUSED BY THE INABILITY OF G-CSF TO INDUCE GADD45Β-MEDIATED GENE DEMETHYLATION AND ACTIVATION OF RETINOIC ACID SIGNALING

EHA Library, Perihan Mir, 295010

PERSISTENCE OF PNH CLONES OVER TIME: INSIGHTS FROM THE MID-TERM ANALYSIS OF THE FRENCH NATION-WIDE MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Orianne Wagner-Ballon, 295011

RESULTS OF THE PEGASUS PHASE III RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR, PEGCETACOPLAN, COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Peter Hillmen, 295012

RELAPSE AND CLONAL EVOLUTION IN SEVERE APLASTIC ANEMIA PATIENTS TREATED WITH IMMUNOSUPPRESSION AND ELTROMBOPAG

EHA Library, Bhavisha Patel, 295013

GENETIC SCREENING OF CHILDREN WITH BONE MARROW FAILURE: THE ROLE OF PRIMARY IMMUNE-DEFICIENCIES

EHA Library, Maurizio Miano, 295014

LARGE SCALE WHOLE GENOME PROFILING OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IDENTIFIES GENOMICALLY DEFINED ULTRA-LOW RISK GROUP

EHA Library, Mehmet Samur, 295015

THE SEARCH FOR OPTIMIZATION STRATEGIES OF MCL-1 INHIBITORS IN MULTIPLE MYELOMA HIGHLIGHTS CONCURRENT BCL-XL TARGETING AND ABCB1 BLOCKADE AS PROMISING THERAPEUTIC STRATEGIES

EHA Library, Arnold Bolomsky, 295016

SINGLE CELL TRANSCRIPTOMIC ANALYSIS OF THE MULTIPLE MYELOMA BONE MARROW IDENTIFIES A UNIQUE INFLAMMATORY STROMAL CELL POPULATION ASSOCIATED WITH MYELOMA CELLS IN-SITU

EHA Library, Tom Cupedo, 295017

CC-93269, A 2+1 T CELL ENGAGER (TCE) TARGETING B-CELL MATURATION ANTIGEN (BCMA) AND CD3Ε, SHOWS ANTITUMOR ACTIVITY IN MULTIPLE MYELOMA PRECLINICAL MODELS

EHA Library, Isaac Boss, 295018

CHARACTERIZATION AND COMPARISON OF MYC REARRANGEMENTS IN PATIENTS WITH MULTIPLE MYELOMA AND OTHER MATURE B-CELL NEOPLASMS

EHA Library, Sonja Seliger, 295019

IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL

EHA Library, Lawrence Radford, 295020

PRIMARY ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

EHA Library, Saad Z. Usmani, 295021

IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Roberto Mina, 295022

BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

EHA Library, Hartmut Goldschmidt, 295023

DEPTH OF RESPONSE TO ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA: INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL

EHA Library, Katja Weisel, 295024

INTERIM RESULTS FROM THE FIRST PHASE 1 CLINICAL STUDY OF THE B-CELL MATURATION ANTIGEN (BCMA) 2+1 T CELL ENGAGER (TCE) CC-93269 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Luciano J. Costa, 295025

A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, María-Victoria Mateos, 295026

MRD EVALUATION BY PET/CT ACCORDING TO DEAUVILLE CRITERIA COMBINED WITH BONE MARROW TECHNIQUES IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS ENROLLED IN THE PHASE II FORTE TRIAL

EHA Library, Elena Zamagni, 295027

FIRST-IN-HUMAN PHASE 1 STUDY OF THE NOVEL CELMOD AGENT CC-92480 COMBINED WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, PAUL RICHARDSON, 295028

IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS

EHA Library, Jesus San Miguel, 295029

SINGLE-CELL MULTI-OMICS REVEALS ABERRANT MEGAKARYOCYTE-PROGENITOR (MKP) SUB-FRACTIONS IN MYELOFIBROSIS (MF) AND IDENTIFIES MUTANT CLONE-SPECIFIC TARGETS

EHA Library, Bethan PSAILA, 295030

RAS/MAPK PATHWAY MUTATIONS ARE ASSOCIATED WITH ADVERSE SURVIVAL OUTCOMES AND MAY PREDICT RESISTANCE TO JAK INHIBITORS IN MYELOFIBROSIS

EHA Library, Giacomo Coltro, 295031

ONCOGENIC KRAS-G12D CAUSES MYELOPROLIFERATION VIA NLRP3 INFLAMMASOME ACTIVATION

EHA Library, Shaima'a Hamarsheh, 295032

EXOME SEQUENCING OF PAIRED MPN AND BLAST PHASE SHOWS AN ACCUMULATION OF SPLICING AND CHROMATIN MODIFYING GENE MUTATIONS, CLONAL EVOLUTION AND GAIN OF RAS PATHWAY MUTATIONS DURING PROGRESSION

EHA Library, Manja Meggendorfer, 295033

PREDICTING THE LONG-TERM EFFICACY OF IFNΑ IN JAK2V617F AND CALR-MUTATED MPN PATIENTS

EHA Library, Amandine Tisserand, 295034

KRT‑232, A FIRST‑IN‑CLASS, MURINE DOUBLE MINUTE 2 INHIBITOR (MDM2I), FOR MYELOFIBROSIS (MF) RELAPSED OR REFRACTORY (R/R) TO JANUS‑ASSOCIATED KINASE INHIBITOR (JAKI) TREATMENT (TX)

EHA Library, Haifa Kathrin Al-Ali, 295035

ADDITION OF PARSACLISIB, A PI3KDELTA INHIBITOR, IN PATIENTS (PTS) WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB (RUX): A PHASE 2 STUDY IN PTS WITH MYELOFIBROSIS (MF)

EHA Library, Abdulraheem Yacoub, 295036

RUXOLITINIB DISCONTINUATION SYNDROME: INCIDENCE, RISK FACTORS AND MANAGEMENT IN 242 PATIENTS WITH MYELOFIBROSIS

EHA Library, Francesca Palandri, 295037

UPDATED RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP, A CD123-TARGETED THERAPY, IN PATIENTS WITH POOR-RISK MYELOFIBROSIS

EHA Library, Naveen Pemmaraju, 295038

EFFICACY AND SAFETY OF MEPOLIZUMAB IN HYPEREOSINOPHILIC SYNDROME: A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

EHA Library, Florence Roufosse, 295039

PET-2-GUIDED ESCALATED BEACOPP FOR PATIENTS WITH ADVANCED NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP

EHA Library, Dennis A. Eichenauer, 295040

CONDITIONAL RELATIVE SURVIVAL IN ADULT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2017

EHA Library, Julia Driessen, 295041

PET-GUIDED TREATMENT IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA: FOLLOW-UP ANALYSIS OF PET-2-NEGATIVE PATIENTS IN THE HD18 TRIAL BY THE GERMAN HODGKIN STUDY GROUP.

EHA Library, Stefanie Kreissl, 295042

PRIMARY THERAPY AND RELATIVE SURVIVAL IN PATIENTS AGED 60 YEARS AND OLDER WITH CLASSICAL HODGKIN LYMPHOMA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2017

EHA Library, Julia Driessen, 295043

RESPONSE-ADAPTED THERAPY WITH NIVOLUMAB + BRENTUXIMAB VEDOTIN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH STANDARD-RISK RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744

EHA Library, Christine Mauz-Körholz, 295044

ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

EHA Library, Meletios Dimopoulos, 295045

IXAZOMIB, RITUXIMAB AND DEXAMETHASONE (IRD) IN PATIENTS WITH RELAPSED OR PROGRESSIVE WALDENSTROM'S MACROBLOBULINEMIA: FINAL ANALYSIS OF THE HOVON124/ECWM-R2 TRIAL

EHA Library, Marie José Kersten, 295046

REAL-WORLD OUTCOME IN MANTLE CELL LYMPHOMA – A STUDY OF RELATIVE AND OVERALL SURVIVAL IN PATIENTS PRIMARILY TREATED WITH R-BENDAMUSTINE, R-CHOP OR THE NORDIC MCL2 REGIMEN IN SWEDEN 2007-2017

EHA Library, Alexandra Albertsson Lindblad, 295047

IBRUTINIB, VENETOCLAX PLUS OBINUTUZUMAB IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS

EHA Library, Steven Le, 295048

IBRUTINIB COMPARED TO IMMUNO-CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RELAPSE OF MANTLE CELL LYMPHOMA: A REPORT FROM FONDAZIONE ITALIANA LINFOMI (FIL) AND EUROPEAN MANTLE CELL LYMPHOMA NETWORK (EMCLN)

EHA Library, Chiara Rusconi, 295049

ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA)

EHA Library, Gerhard Held, 295050

QUANTITATIVE PARAMETERS FROM INTERIM PET/CT AFTER TWO R-CHOP14 CYCLES IDENTIFY POOR-RISK DLBCL PATIENTS: RESULTS FROM THE PROSPECTIVE SAKK38/07 CLINICAL STUDY

EHA Library, Emanuele Zucca, 295051

INOTUZUMAB OZOGAMICIN PLUS R-CVP IS A FEASIBLE AND EFFECTIVE REGIMEN FOR FRONTLINE TREATMENT OF DLBCL IN PATIENTS WHO ARE UNFIT FOR R-CHOP: RESULTS OF A RANDOMISED PHASE 2 UK NCRI TRIAL

EHA Library, Elizabeth Phillips, 295052

INITIAL RESULTS OF A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Carmelo Carlo-Stella, 295053

EFFICACY AND SAFETY OF ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAS: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

EHA Library, Charles Herbaux, 295054

OUTCOME OF LIMITED STAGE PERIPHERAL T-CELL LYMPHOMA AFTER CHOP(-LIKE) THERAPY: A POPULATION BASED STUDY OF 251 PATIENTS FROM THE NORDIC LYMPHOMA EPIDEMIOLOGY GROUP

EHA Library, Ahmed Ludvigsen Al-Mashhadi, 295055

HIGH DOSE METHOTREXATE CNS PROPHYLAXIS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A MULTICENTRE ANALYSIS OF TOXICITY AND IMPACT ON R-CHOP DELIVERY

EHA Library, Matthew Wilson, 295056